Gyrolab® xPand immunoassay system
Gyrolab xPand is a high-throughput, compact disk (CD) based microfluidic immunoassay platform for unattended parallel processing of up to 5 CDs, generating 560 data points in 5 hours.
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
Great replacement for ELISA.
Antibody binding to analyte
The Gyrolabs instrument basically runs the whole ELISA for you. All you need to do is prepare the samples and antibodies just like you do for normal ELISA. The instrument takes care of adding each component and washing in between steps. You walk away after loading samples and CD. After about 1 hour, the data is ready for analysis.
Review Date: 29 Oct 2020 | Gyros Protein Technologies
High-throughput with good quality and reproducibility.
Analysing drug concentration in plasma or serum
High quality and reproducibility.
Review Date: 22 Oct 2020 | Gyros Protein Technologies
Key Features:
- Run up to five CDs unattended to generate up to 560 immunoassay data points within five hours
- On-deck cooling of samples and reagents
- Mix and match methods/CDs in a single run
- Flexible run setup and analysis
- Software 21 CFR part 11 compliant
- Backed by industry-leading technical support
- Nanoliter-scale, rapid analysis, and wide dynamic range
High-throughput, automated analysis of viral vector titer and process related impurities
Download this application note to see a study that explores a solution to these challenges, by investigating the utility and performance of analyzing viral vector titer and impurities in a continuous 5-CD run (“Gyroplex® panel”) using the Gyrolab® xPand platform and a combination of Gyrolab kits and assay protocols. Two AAV serotypes (AAV2 and AAV9) plus 3 impurities (host-cell proteins [HCPs], endonuclease, and transferrin) were analyzed for each serotype on one instrument.
Your guide to miniaturized immunoassays for biotherapeutics
Building on advances in microfluidics, next-generation immunoassays offer unparalleled capability in automation and miniaturization, generating robust and reproducible results for faster decision-making.
In this eBook, discover the advantages of automated, miniaturized immunoassays across the drug development pathway, from pre-clinical to bioprocessing. Learn about challenges and trends in immunoassay technology and how automated, miniaturized immunoassays can help you maximize productivity across a range of biopharmaceutical applications, including:
- Research and clinical development
- Insulin quantification
- Anti-drug antibody studies
- In-solution affinity determination
- Vaccine development and production
In-solution affinity determination using Gyrolab systems
In this technical note, Gyros Protein Technologies demonstrates how using Gyrolab systems can simplify the accurate and rapid analysis of high affinity ligands to determine affinity and activity.
Automated approaches to improving immunoassays - SelectScience and Gyros Protein Technologies Podcast
At the Bioprocessing Summit in Boston, SelectScience® spoke with Todd Glynn from Gyros Protein Technologies for this special Podcast.
We spoke about the Gyrolab® immunoassay kits and solutions for cell and gene therapy viral vector titer and impurity analysis, and how they benefit their customers.
Anti-AAV antibody testing emerges as key to gene therapy
Advance gene therapy precision by reliably testing pre-existing AAV immunogenicity
How immunoassay innovation has expanded the biotherapeutic development toolbox
Experts share how commitment to bioanalytical innovation and quality has enabled success in biotherapeutic development
Automated approaches to improving immunoassays
Find out how the immunoassay kits from Gyros Protein Technologies can support your cell and gene therapy viral vector titer and impurity analyses
Gene therapy: Reliable capsid titer quantification for AAV-based therapeutics
Guest editorial: Technology to meet the challenge of efficiency in the regulated AAV vector space
New ultra-sensitive, automated immunoassays to streamline biopharma clinical assay development
EMD Serono senior scientist Carina Carter shares her experience with some of the latest immunoassay technology optimizing pharmacokinetics and immunogenicity assay development
